180 related articles for article (PubMed ID: 20408074)
41. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
[TBL] [Abstract][Full Text] [Related]
42. Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure.
Goktas A; Goktas S; Atas M; Demircan S; Yurtsever Y
Cutan Ocul Toxicol; 2013 Mar; 32(1):23-6. PubMed ID: 22737998
[TBL] [Abstract][Full Text] [Related]
43. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
Fuest M; Kotliar K; Walter P; Plange N
Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
[TBL] [Abstract][Full Text] [Related]
44. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis).
Sharei V; Höhn F; Köhler T; Hattenbach LO; Mirshahi A
Eur J Ophthalmol; 2010; 20(1):174-9. PubMed ID: 19927267
[TBL] [Abstract][Full Text] [Related]
45. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections.
Adelman RA; Zheng Q; Mayer HR
J Ocul Pharmacol Ther; 2010 Feb; 26(1):105-10. PubMed ID: 20187807
[TBL] [Abstract][Full Text] [Related]
46. [Topical application of hypotensive drugs for the prevention of intraocular pressure elevation after intravitreal injections of anti-VEGF drugs].
Andreeva YS; Alkharki L; Shelankova AV; Budzinskaya MV
Vestn Oftalmol; 2024; 140(2. Vyp. 2):73-79. PubMed ID: 38739134
[TBL] [Abstract][Full Text] [Related]
47. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection.
Lee K; Yang H; Lim H; Lew HM
Retina; 2009; 29(10):1409-17. PubMed ID: 19816242
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of brimonidine in preventing intraocular pressure spikes following phacoemulsification in glaucoma patients.
Kandarakis A; Soumplis V; Karampelas M; Panos C; Kyriakos N; Baxevanakis A; Karagiannis D
Eur J Ophthalmol; 2010; 20(6):994-9. PubMed ID: 20544673
[TBL] [Abstract][Full Text] [Related]
49. Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application.
Höhn F; Mirshahi A
Graefes Arch Clin Exp Ophthalmol; 2010 Oct; 248(10):1371-5. PubMed ID: 20407785
[TBL] [Abstract][Full Text] [Related]
50. Effects of crystalloid versus colloid and the α-2 agonist brimonidine versus placebo on intraocular pressure during prone spine surgery: a factorial randomized trial.
Farag E; Sessler DI; Kovaci B; Wang L; Mascha EJ; Bell G; Kalfas I; Rockwood E; Kurz A
Anesthesiology; 2012 Apr; 116(4):807-15. PubMed ID: 22322966
[TBL] [Abstract][Full Text] [Related]
51. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
[TBL] [Abstract][Full Text] [Related]
52. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study.
Song S; Yu XB; Dai H
Indian J Ophthalmol; 2016 Oct; 64(10):762-766. PubMed ID: 27905340
[TBL] [Abstract][Full Text] [Related]
53. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab].
Wu L; Evans T
Arch Soc Esp Oftalmol; 2010 Nov; 85(11):364-9. PubMed ID: 21277463
[TBL] [Abstract][Full Text] [Related]
54. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab.
Bakri SJ; Pulido JS; McCannel CA; Hodge DO; Diehl N; Hillemeier J
Eye (Lond); 2009 Jan; 23(1):181-5. PubMed ID: 17693999
[TBL] [Abstract][Full Text] [Related]
55. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
Yeom HY; Lee JH; Hong YJ; Seong GJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678
[TBL] [Abstract][Full Text] [Related]
56. Efficacy, safety, and current applications of brimonidine.
Fudemberg SJ; Batiste C; Katz LJ
Expert Opin Drug Saf; 2008 Nov; 7(6):795-9. PubMed ID: 18983225
[TBL] [Abstract][Full Text] [Related]
57. Timolol 0.1% gel versus timolol 0.5% eyedrops in the prophylaxis of ocular hypertension after phacoemulsification surgery.
Cagini C; Di Pasquale G; Lupidi M; Cerquaglia A; Pascale A; Boccolucci A; Fiore T
Eur J Ophthalmol; 2014; 24(6):857-61. PubMed ID: 24760603
[TBL] [Abstract][Full Text] [Related]
58. [Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension].
Puerto-Hernández B; Rebolleda G; García-Pérez JL; Muñoz-Negrete FJ; González-Gordaliza C
Arch Soc Esp Oftalmol; 2011 Feb; 86(2):42-6. PubMed ID: 21440829
[TBL] [Abstract][Full Text] [Related]
59. Double-masked three-period crossover investigation of timolol in control of raised intraocular pressure.
Campbell SH; Hickey-Dwyer M; Harding SP
Eye (Lond); 1993; 7 ( Pt 1)():105-8. PubMed ID: 8325398
[TBL] [Abstract][Full Text] [Related]
60. [Hypotensive effect of three different formulations of brimonidine tartrate in normal eyes].
Abud TB; Scuoteguazza Filho M; Oliveira ES; Abud JF; Prata Junior JA
Arq Bras Oftalmol; 2013; 76(2):69-71. PubMed ID: 23828464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
